New 52 Week Low Today

NovAccess Global Inc XSNX:OTCQB

*Data is delayed | Exchange | USD
Last | 05/10/24 EDT
0.007quote price arrow up+0.001 (+16.6667%)
Volume
569,500
52 week range
0.00 - 0.22
Loading...
  • Open0.0061
  • Day High0.007
  • Day Low0.0047
  • Prev Close0.006
  • 52 Week High0.22
  • 52 Week High Date05/24/23
  • 52 Week Low0.00
  • 52 Week Low Date05/10/24

Key Stats

  • Market Cap193,715.006
  • Shares Out27.67M
  • 10 Day Average Volume974,050.33
  • Dividend-
  • Dividend Yield-
  • Beta1.64
  • YTD % Change-65.09

KEY STATS

  • Open0.0061
  • Day High0.007
  • Day Low0.0047
  • Prev Close0.006
  • 52 Week High0.22
  • 52 Week High Date05/24/23
  • 52 Week Low0.00
  • 52 Week Low Date05/10/24
  • Market Cap193,715.006
  • Shares Out27.67M
  • 10 Day Average Volume974,050.33
  • Dividend-
  • Dividend Yield-
  • Beta1.64
  • YTD % Change-65.09

RATIOS/PROFITABILITY

  • EPS (TTM)-0.10
  • P/E (TTM)-0.07
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-2.207M
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)56.61%
  • Net Margin (TTM)298.20%
  • Debt To Equity (MRQ)-34.02%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NovAccess Global Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in...
John Cassarini
Independent Chairman of the Board
Dwain Moris - Irvin Ph.D.
Chief Executive Officer, Director
Neil Laird
Fractional Chief Financial Officer
Address
8584 E. WASHINGTON STREET, NO. 127
Chagrin Falls, OH
44023
United States